Absorption, distribution, metabolism and excretion of hyaluronic acid during pregnancy: a matter of molecular weight.


Journal

Expert opinion on drug metabolism & toxicology
ISSN: 1744-7607
Titre abrégé: Expert Opin Drug Metab Toxicol
Pays: England
ID NLM: 101228422

Informations de publication

Date de publication:
Jul 2021
Historique:
pubmed: 18 5 2021
medline: 6 8 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

For many years hyaluronic acid (HA) was mainly used for its hydrating properties. However, new applications have recently arisen, considering the biological properties of HA and its molecular weight. Clinical application of low molecular weight HA (LMW-HA) initially was supported by specific absorption data. The identification of high molecular weight HA (HMW-HA) absorption pathways and the knowledge of its physiological role allowed to evaluate its clinical application. Based on the immunomodulatory properties of HMW-HA and its physiological involvement as signaling molecule, pregnancy represents an interesting context of application. This expert opinion includes in-vitro, in-vivo, ex-vivo and clinical studies on gestational models. It provides an overview of the physiological and the therapeutic role of HMW-HA in pregnancy starting from its metabolism. Indeed, HMW-HA is widely involved in several physiological processes as implantation, immune response, uterine quiescence and cervical remodeling, and therefore is an essential molecule for a successful pregnancy. Available evidence suggests that HMW-HA administration can support physiological pregnancy, favoring blastocyst adhesion and development, preventing miscarriage and pre-term birth. For this reason, supplementation in pregnancy should be evaluated.

Identifiants

pubmed: 33999749
doi: 10.1080/17425255.2021.1931682
doi:

Substances chimiques

Adjuvants, Immunologic 0
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

823-840

Auteurs

Vittorio Unfer (V)

Systems Biology Group Lab, Rome, Italy.

Marco Tilotta (M)

R&D Department,Lo.Li. Pharma S.r.l., Rome, Italy.

Cihan Kaya (C)

Department of Obstetrics and Gynaecology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Marco Noventa (M)

Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, Padua, Italy.

Péter Török (P)

Faculty of Medicine, Institute of Obstetrics and Gynecology, University of Debrecen, Hungary.

Ibrahim Alkatout (I)

Department of Obstetrics and Gynecology, University Hospital Schleswig Holstein, Kiel, Germany.

Georgios Gitas (G)

Department of Obstetrics and Gynecology, University Hospital Schleswig Holstein, Lübeck, Germany.

Gabriele Bilotta (G)

Alma Res Fertility Center, Rome, Italy.

Antonio Simone Laganà (AS)

Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital,University of Insubria, Varese, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH